Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Brains On-Line
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Consumables, Central Supplies
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
Drug Discovery Tools
- Drug Discovery Tools